Abstract
Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Current Alzheimer Research
Title:Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice
Volume: 11 Issue: 10
Author(s): Elise Levigoureux, Sophie Lancelot, Caroline Bouillot, Fabien Chauveau, Mathieu Verdurand, Jeremy Verchere, Thierry Billard, Thierry Baron and Luc Zimmer
Affiliation:
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Abstract: Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Export Options
About this article
Cite this article as:
Levigoureux Elise, Lancelot Sophie, Bouillot Caroline, Chauveau Fabien, Verdurand Mathieu, Verchere Jeremy, Billard Thierry, Baron Thierry and Zimmer Luc, Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice, Current Alzheimer Research 2014; 11(10) . https://dx.doi.org/10.2174/1567205011666141107154201
DOI https://dx.doi.org/10.2174/1567205011666141107154201 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Targeting Neurite Growth Inhibitors to Induce CNS Regeneration
Current Pharmaceutical Design PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
Current Medicinal Chemistry Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic Review
Current Pharmaceutical Design The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Current Pharmaceutical Design Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Current Pharmaceutical Design Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design